Age-related histological and zinc content changes in adult nonhyperplastic prostate glands

Aoki Y, Arai Y, Maeda H, Okubo K, Shinohara K (2001) Racial differences in cellular composition of benign prostatic hyperplasia. Prostate 49:243–250 Arenas MI, Romo E, Royuela M, Ruiz A, Fraile B, Sánchez-Chapado M, Paniagua R (2001) Morphometric evaluation of the human prostate. Int J Androl 24:37–47 Avtandilov GG (1973) Morphometry in pathology. Medicina, Moscow Babinski MA, Chagas MA, Costa WS, Sampaio FJ (2003) Prostatic epithelial and luminal area in the transition zone acini: morphometric analysis in normal and hyperplastic human prostate. BJU Int 92:592–596 Bartsch G, Mikuz G, Dietze O, Rohr HP (1989) Morphometry in the abnormal growth of the prostate. In: Fitzpatrick JM, Krane RJ (eds) The Prostate. Churchill Livingstone, Edinburgh, pp 19–31 Bartsch G, Muller HR, Oberholzer M, Rohr HP (1979) Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122:487–491 Bataineh ZM, Bani Hani IH, Al-Alami JR (2002) Zinc in normal and pathological human prostate gland. Saudi Med J 23:218–220 Beck FW, Prasad AS, Butler CE, Sakr WA, Kucuk O, Sarkar FH (2004) Differential expression of hZnT-4 in human prostate tissues. Prostate 58:374–381 Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostate hyperplasia with age. J Urol 132:474–479 Blok LJ, Grossmann ME, Perry JE, Tindall DJ (1995) Characterization of an early growth response gene, which encodes a zinc finger transcription factor, potentially involved in cell cycle regulation. Mol Endocrinol 9(11):1610–1620 Bonkhoff H, Remberger K (1998) Morphogenesis of benign prostatic hyperplasia and prostatic carcinoma. Pathologe 19:12–20 Bozym RA, Chimienti F, Giblin LJ, Gross GW, Korichneva I, Li Y, Libert S, Maret W, Parviz M, Frederickson CJ, Thompson RB (2010) Free zinc ions outside a narrow concentration range are toxic to a variety of cells in vitro. Exp Biol Med (Maywood) 235(6):741–750 Campbell B (2005) High rate of prostate symptoms among Ariaal men from Northern Kenya. Prostate 62:83–90 Carson C, Rittmaster R (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61(Suppl 1):2–7 Carter HB, Coffey DS (1990) The prostate: an increasing medical problem. Prostate 16:39–48 Chagas MA, Babinski MA, Costa WS, Sampaio FJB (2002) Stromal and acinar components of the transition zone in normal and hyperplastic human prostate. BJU Int 89:699–702 Chandra RK (1984) Excessive intake of zinc impairs immune responses. JAMA 252(11):1443–1446 Coleman JE (1992) Zinc proteins: enzymes, storage proteins, transcription factors, and replication proteins. Annu Rev Biochem 61:897–946 Costello LC, Franklin RB (1998) Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 35:285–296 Costello LC, Franklin RB (2006) The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 5:17–30 Costello LC, Franklin RB, Feng P, Tan M, Bagasra O (2005) Zinc and prostate cancer. A critical scientific, medical and public interest issue (United States). Cancer Causes Control 16:901–915 Cunha GR, Hayward SW, Wang YZ, Ricke WA (2003) Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 107:1–10 Deering RE, Choongkittaworn M, Bigler SA, Aramburu E, King J, Brawer MK (1994) Morphometric quantitation of stroma in human benign prostatic hyperplasia. Urology 44:64–67 Deng FM, Xia TL, Gu FL et al (1995) A quantitative morphometry of the normal and the benign hyperplastic prostate in Chinese. Chinese J Urol 12 Desouki MM, Geradts J, Milon B, Franklin RB, Costello LC (2007) hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands. Mol Cancer 6:37–44 Dhar NK, Goel TC, Dube PC, Chowdhury AR, Kar AB (1973) Distribution and concentration of zinc in the subcellular fractions of benign hyperplastic and malignant neoplastic human prostate. Exp Mol Pathol 19:139–142 Djavan B, Remzi M, Erne B, Marberger M (2002) The pathophysiology of benign prostatic hyperplasia. Drugs Today (Barc) 38(12):867–876 Doehring CB, Sanda MG, Partin AW, Sauvageot J, Juo H, Beaty H, Epstein JI, Hill G, Walsh PC (1996) Histopathologic characterization of hereditary benign prostatic hyperplasia. Urology 48:650–653 Dutkiewicz S (1995) Zinc and magnesium serum levels in patients with benign prostatic hyperplasia (BPH) before and after prazosin therapy. Mater Med Pol 27:15–17 Ekmekcioglu C (2001) The role of trace elements for the health of elderly individuals. Nahrung 45:309–316 Fibbi B, Penna G, Morelli A, Adorini L, Maggi M (2010) Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 33:475–488 Franklin RB, Feng P, Milon B, Desouki M, Singh KK, Kajdacsy-Balla A, Bagasra O, Costello LC (2005) hZIPI zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer 4:32–45 Guntupalli JN, Padala S, Gummuluri AV, Muktineni RK, Byreddy SR, Sreerama L, Kedarisetti PC, Angalakuduru DP, Satti BR, Venkatathri V, Pullela VB, Gavarasana S (2007) Trace elemental analysis of normal, benign, hypertrophic and cancerous tissues of the prostate gland using the particle-induced X-ray emission technique. Eur J Cancer Prev 16:108–115 Györkey F (1973) Some aspects of cancer of the prostate gland. In: Busch H (ed) Methods in cancer research, vol 10. Academic, New York, pp 279–386 Haidinger G, Madersbacher S, Walderhoer T, Lunglmayr G, Vutuc C (1999) The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables. Eur J Epidemiol 15:717–722 Hienzsch E, Schneider H-J, Anke M (1970) Vergleichende Untersuchungen zum Mengen- und Spurenelementgehalt der normalen Prostata, des Prostataadenoms und des Prostatakarzinoms. Z Urol Nephrol 63:543–546 High KP (2001) Nutritional strategies to boost immunity and prevent infection in elderly individuals. Clin Infect Dis 33:1892–1900 Ho CK, Habib FK (2011) Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol 8:29–41 Hoare R, Delory GE, Penner DW (1956) Zinc and acid phosphatase in the human prostate. Cancer 9:721–726 Holmes MD, Pollak MN, Willett WC, Hankinson SE (2002) Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11:852–861 ICRP (International Commission on Radiological Protection) (1975) Report no. 23 of the Task Group on reference Man. Pergamon, Oxford Ide-Ektessabi A, Fujisawa F, Sugiruma K, Kitamura Y, Gotoh A (2002) Quantitative analysis of zinc in prostate cancer tissue using synchrotron radiation microbeams. X-Ray Spectrom 31:7–11 Iyengar GV (1998) Reevaluation of the trace element content in reference men. Radiat Phys Chem 51:545–560 Iyengar GV, Kollmer WE, Bowen HGM (1978) The elemental composition of human tissues and body fluids. A compilation of values for adults, Verlag Chemie, Weinheim Jacobsen SJ (2007) Risk factors for benign prostatic hyperplasia. Current Urol Reports 8:281–288 Kar AB, Chowdhury AR (1968) Distribution of zinc in the subcellular fractions of human prostate. Curr Sci 37:375–376 Kim HS, Lee SW, Kim EK, Cho JM, Han KH, Kang JY, Yoo TK (2009) Relationships between relative proportion of tissue components, urodynamic parameters, and low urinary tract symptoms in patients with benign prostatic hyperplasia. Korean J Urol 50:859–864 Kontargiris E, Vadalouka A, Ragos V, Kalfakakou V (2012) Zinc inhibits apoptosis and maintains NEP downregulation, induced by ropivacaine, in HaCaT cells. Biol Trace Elem Res 150:460–466 Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM (2008) Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 167(8):925–934 Lagiou P, Mantzoros CS, Tzonou A, Signorello LB, Lipworth L, Trichopoulos D (1997) Serum steroids in relation to benign prostatic hyperplasia. Oncology 54:497–501 Leake A, Chrisholm GD, Busuttil A, Habib FK (1984) Subcellular distribution of zinc in the benign and malignant human prostate: evidence for a direct zinc androgen interaction. Acta Endocrinol (Copenh) 105(2):281–288 Leake A, Chisholm GD, Habib FK (1983) The distribution of zinc in human prostate. Prostate 4:421–422 Lee KL, Peehl DM (2004) Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol Nov 172(5 Pt 1):1784–1791 Leissner KM, Fielkegard B, Tisell L-E (1980) Concentration and content of zinc in human prostate. Invest Urol 18:32–35 Lepor H (2005) Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol 7(suppl 4):S3–S12 Li W, Wu C-L, Febbo PG, Olumi AF (2007) Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol 171:1189–1198 Liang D, Yang M, Guo B, Cao J, Yang L, Guo X, Li Y, Gao Z (2012) Zinc inhibits H2O2-induced MC3T3-E1 cells apoptosis via MAPK and PI3K/AKT pathways. Biol Trace Elem Res 148:420–429 Matsuda T, Fujime M, Suda K (2006) Relationship between the prostatic tissue components and natural history of benign prostatic hyperplasia. Anal Quant Cytol Histol 28:121–124 Matusik RJ, Kreis C, McNicol P, Sweetland R, Mullin C, Fleming WH, Dodd JG (1986) Regulation of prostatic genes: role of androgens and zinc in gene expression. Biochem Cell Biol 64:601–607 Mawson CA, Fischer MJ (1952) The occurrence of zinc in the human prostate gland. Can J Med Sci 30:336–339 McNeal JE (1978) Origin and evolution of benign prostatic enlargement. Invest Urol 15:340–345 Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB (2002) Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54:935–944 Miller AL (1996) Benign prostatic hyperplasia. Nutritional and botanical therapeutic options. Alt Med Rev 1:18–25 Mocchegiani E, Muaaioli M, Giacconi R (2000) Zinc, metallothioneins, immune responses, survival and ageing. Biogeront 1:133–143 Morita H (1981) Histochemical study of human prostate. II. Ultrastructural and XMA observation of zinc in the hyperplastic and neoplastic prostate. Jpn J Urol 72:717–729 Nemoto K, Kondo Y, Himeno S, Suzuki Y, Hara S, Akimoto M, Imura N (2000) Modulation of telomerase activity by zinc in human prostatic and renal cancer cells. Biochem Pharmacol 59:401–405 Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82(4–5):184–199 Nickel JC (2008) Inflammation and benign prostatic hyperplasia. Urol Clin North Am 35(1):109–115 Oldereid NB, Thomassen Y, Attramadal A, Olaisen B, Purvis K (1993) Concentrations of lead, cadmium and zinc in the tissues of reproductive organs of men. J Reprod Fertil 99:421–425 Padro L, Benacer R, Foix S, Maestre E, Murillo S, Sanvicens E, Somoza D, Ngo J, Cervera P (2002) Assessment of dietary adequacy for an elderly population based on a Mediterranean model. J Nutrit Health Aging 6:31–33 Picurelli L, Olcina PV, Roig MD, Ferrer J (1991) Determination of Fe, Mg, Cu, and Zn in normal and pathological prostatic tissue. Actas Urol Esp 15:344–350 Pirus YF (2006) The male prostate morphological changes in postnatal ontogenesis. Ph.D. dissertation. Ternopil State Medical University of the Ministry of Public Health of Ukraine, Ternopil Prasad AS, Mantzoros CS, Beck FW, Hess JW, Brewer GJ (1996) Zinc status and serum testosterone levels of healthy adults. Nutrition 12:344–348 Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, De La Taille A (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69(16):1774–1780 Samman S, Roberts DC (1988) The effect of zinc supplements on lipoproteins and copper status. Atherosclerosis 70:247–252 Sapota A, Daragó A, Taczalski J, Kilanowicz A (2009) Disturbed homeostasis of zinc and other essential elements in the prostate gland dependent on the character of pathological lesions. Biometals 22:1041–1049 Schauer IG, Rowley DR (2011) The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 82(4–5):200–210 Schwartz MK (1975) Role of trace elements in cancer. Cancer Res 35:3481–3487 Sciarra F, Toscano V (2000) Role of estrogens in human benign prostatic hyperplasia. Arch Androl 2000:213–220 Shapiro E, Hartanto V, Perlman EJ, Tang R, Wang B, Lepor H (1997) Morphometric analysis of pediatric and nonhyperplastic prostate glands: evidence that BPH is not a unique stromal process. Prostate 33:177–182 Siegal E, Graig FA, Drystall MM, Siegal EP (1961) Distribution of 65Zn in the prostate and other organs of man. Br J Cancer 15:647–664 Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS (1996) Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56:218–226 Thomas JA (1999) Diet, micronutrients, and the prostate gland. Nutr Rev 57:95–103 Tisell L-E, Fjelkegard B, Leissner KH (1982) Zinc concentration and content of the dorsal, lateral and medial prostatic lobes and of periurethral adenomas in man. J Urol 128:403–405 Trueman P, Hood SC, Nayak US, Mrazek MF (1999) Prevalence of lower urinary tract symptoms and self-reported ‘benign prostatic hyperplasia’ and their effect on quality of life in a community-based survey of men in the UK. Br Int J Urol 83:410–415 Truong-Tran AQ, Ho LH, Chai F, Zalewski PD (2000) Cellular zinc fluxes and the regulation of apoptosis/gene-directed cell death. J Nutr 130(5S Suppl):1459S–1466S Tvedt KE, Halgunset J, Kopstad G, Haugen OA (1989) Intracellular distribution of calcium and zinc in normal, hyperplastic, and neoplastic human prostate: X-ray microanalysis of freeze-dried cryosections. Prostate 15:41–51 Vaquero MP (2002) Magnesium and trace elements in the elderly: intake, status and recommendations. J Nutrit Health Aging 6:147–153 Weibel ER, Gomez DM (1962) A principle for counting tissue structures on random sections. J Appl Phys 17:343–348 Woodard HQ, White DR (1986) The composition of body tissues. Br J Radiol 59:1209–1218 Zaichick V (2004) Losses of chemical elements in biological samples under the dry aching process. Trace Elem Med 5(3):17–22 Zaichick V, Sviridova T, Zaichick S (1996) Zinc concentration in human prostatic fluid: normal, chronic prostatitis, adenoma, and cancer. Int Urol Nephrol 28:687–694 Zaichick V, Sviridova T, Zaichick S (1997) Zinc in human prostate gland: normal, hyperplastic and cancerous. Int Urol Nephrol 29:565–574 Zaichick S, Zaichick V (2010) Method and portable facility for energy-dispersive X-ray fluorescent analysis of zinc content in needle-biopsy specimens of prostate. X-Ray Spectrom 39:83–89 Zaichick S, Zaichick V (2011) The Br, Fe, Rb, Sr, and Zn content and interrelation in intact and morphologic normal prostate tissue of adult men investigated by energy dispersive X-ray fluorescent analysis. X-Ray Spectrom 40:464–469 Zezerov YG (2001) Hormonal and molecular-biological factors of prostate cancer pathogenesis. Voprosy Oncologii 47(2):174–181 Zhang X, Liang D, Guo B, Yang L, Wang L, Ma J (2012) Zinc inhibits high glucose-induced apoptosis in peritoneal mesothelial cells. Biol Trace Elem Res 150:424–432